See the DrugPatentWatch profile for bosentan

Based on the information available, liver function improvement is not a prerequisite for continuing bosentan treatment. However, regular monitoring of liver function is crucial for patients taking bosentan due to the potential for hepatotoxicity [1].

Bosentan is a medication used to treat pulmonary arterial hypertension (PAH) [1]. It is an endothelin receptor antagonist that works by blocking the action of endothelin, a substance in the body that causes blood vessels to narrow [1].

The United States Food and Drug Administration (FDA) has approved bosentan for the treatment of PAH, but it comes with a boxed warning regarding the risk of liver damage [1]. Regular monitoring of liver function is necessary for patients taking bosentan, and the drug should be discontinued if significant liver injury is suspected [1].

However, the FDA does not specify that liver function improvement is necessary to continue bosentan treatment [1]. Instead, the focus is on regular monitoring to detect and manage any potential liver damage as early as possible [1].

In conclusion, while liver function improvement is not necessary to continue bosentan treatment, regular monitoring of liver function is crucial for patients taking this medication. If you have any concerns about your liver function or bosentan treatment, you should consult your healthcare provider.

Sources:
[1] DrugPatentWatch.com. (n.d.). Bosentan. Retrieved from <https://www.drugpatentwatch.com/drugs/bosentan>